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Abstract  With  new  irradiation  techniques,  the  dose  can  be  better  matched  to  the  contours  of
the tumour.  The  corollary  is  that  greater  precision  is  required.  Recent  intercomparison  studies  of
treatment  plans  have  emphasized  the  need  to  harmonise  contouring  practices.  More  of  a  consen-
sus approach  is  based  on  using  adaptive  imaging  modalities,  expert  group  recommendations  and
automatic segmentation  atlases,  on  harmonisation  of  dosimetric  decisions  through  employing
exhaustive  nomograms  for  organs  at  risk,  and  on  indexes  for  choosing  optimal  treatment  plans.
On another  level,  quality  assurance  and  data  pooling  programmes  have  been  set  up,  making  use
of DICOM-RT  data  transfer  (image  networks).  The  combination  of  several  irradiation  techniques
(for example,  intensity-modulated  conformal  radiation  therapy  plus  CyberKnife® boost  and  re-
irradiation),  making  it  possible  to  irradiate  tumours  better,  requires  the  cumulative  doses  to
be recorded  by  dose  summation  software.  Real  awareness  has  been  achieved  in  recent  years  as
regards improving  the  quality  of  treatment,  pooling  data  and  harmonising  practices.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.New  techniques,  such  as  intensity-modulated  conformal  radiotherapy  (IMCRT)  and  its
development,  modulated  arc  therapy  (RapidArc® VMAT,  and  tomotherapy),  or  even  stereo-
tactic  radiotherapy,  have  better  conformation  capacity.  Less  volume  of  healthy  tissue  is
irradiated  with  high  doses,  but  the  down  side  is  that,  since  at  several  millimetres  from  the
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tumour  dose  gradients  are  abrupt,  the  dose  may  be  sub-
tumoricidal.  These  new  techniques  therefore  go  hand  in
hand  with  a  greater  requirement  for  treatment  quality  in
terms  of  contouring.  Better  documentation  of  the  effects
on  organs  at  risk,  including  structures,  which  were  not  pre-
viously  explored  for  lack  of  the  means  of  sparing  them,
is  now  possible.  For  critical  organs  delineated,  the  doses
delivered  (in  particular,  maximal  doses  and  doses  delivered
per  unit  or  per  percentage  of  the  volume  of  the  organs  at
risk),  can  now  be  compared  with  the  theoretical  or  empirical
doses  according,  for  example,  to  Emami’s  nomograms,  or  to
newly  constructed  nomograms  for  previously  non-contoured
structures.  This  accurate  and  exhaustive  contouring  require-
ment  is  time-consuming  and  demands  continuous  training  for
radiotherapists  to  keep  up  to  date,  necessitating  training
programmes,  the  development  of  computer  tools  and  data
exchange,  particularly  via  image  networks.  These  tools  will
result  in  greater  precision  and  ideally  should  contribute  to
better  reproducibility  and  the  standardisation  of  irradiation
practices.  We  shall  now  brieﬂy  describe  current  practices
and  the  resources  used.
Contouring quality, the contribution of
imaging and the clinical implications
If  contouring  the  tumour  is  inadequate,  coverage  of  its  tar-
get  volume  may  be  reduced.  The  relative  vagueness  that
there  used  to  be  in  deﬁning  target  volumes  with  2D  is
no  longer  possible  with  irradiation  techniques  that  have
a  high  conformity  index  for  maintaining  at  least  equiva-
lent  locoregional  control  of  tumours.  The  reports  50  and
62  of  the  International  Commission  on  Radiation  Units  &
Measurements  (ICRU)  (www.icru.org)  deﬁned  target  volume
concepts:  Gross  Tumour  Volume  (GTV),  the  probability  of
its  microscopic  extension  corresponding  to  the  Clinical  Tar-
get  Volume  (CTV),  margins  to  be  applied  depending  on
movement  of  the  organ  (Internal  Target  Volume  [ITV]),  mar-
gins  to  be  applied  to  take  account  of  patient  repositioning
uncertainties  [1].  These  reports  did  not  evoke  the  problem
Figure 1. Artefacts of dental origin preventing any satisfactory inte
metaplasia of the cervical platysma myocutaneous ﬂap (T2 hypersignal, 
dissection and irradiation (b). Absence of locoregional recurrence of the
mobile tongue.
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f  radioanatomical  GTV  delineation  uncertainties  nor  of
ariability  in  deﬁning  the  clinical  history  of  the  CTV.  The
ncertainties  are  largely  related  to  a  human  factor  and  can
nﬂuence  irradiation  results.  Intra-  and  interobserver  vari-
tions  in  delineation  can  sometimes  be  more  signiﬁcant
han  patient  repositioning  uncertainties.  Many  teams  are
eginning  to  propose  recommendations  or  atlases  so  as  to
tandardise  practices  and  reduce  the  range  of  contouring
ncertainties  [2],  which  along  with  contouring  variability,
re  multifactorial.  They  depend,  for  target  volumes,  on  the
perator’s  (the  radiotherapist’s)  knowledge,  on  the  natu-
al  history  of  the  disease,  and  on  the  speciﬁc  points  noted
n  the  patient’s  medical  records  (the  clinical  description
f  extensions  of  the  disease,  the  precision  of  the  postop-
rative  report,  with  a  detailed  description  of  the  lesions
nd  the  quality  of  peroperative  margins  by  the  surgeon,
nd  the  documentary  level  of  the  histology  report  based  on
he  surgeon’s  focused  description).  In  many  cases  this  step
equires  close  consultation  between  the  various  special-
ies  —the  radiotherapist,  the  radiologist  and  the  surgeon  —
n  particular  when  the  patient  has  not  been  seen  clini-
ally  preoperatively.  These  uncertainties  and  the  contouring
ariability  also  depend  on  the  imaging  modalities  used  for
ontouring  and  the  frames  used.  Artefacts,  such  as  arte-
acts  related  to  dental  material  close  to  a tumour  of  the
uccal  cavity  (Figs.  1  and  2)  or  to  a  hip  prosthesis  in  relation
o  a  pelvic  tumour,  can  increase  contouring  uncertainties
n  a  target  volume  scan.  On  tomotherapy  scans  (megavolt-
ge  in  contrast  to  the  kilovoltage  used  during  the  dosimetry
can)  these  artefacts  are  reduced.  A  contrast-enhanced  scan
rovides  essential  information  in  certain  locations  such  the
ead  and  neck,  with  a  carcinoma  in  situ  (Fig.  3):  there
s  better  contrast  between  the  tumour  and  adjacent  tis-
ues,  better  discrimination  of  the  lymph  node  relative  to
he  vessels  and  to  adenopathies  [3],  or,  in  the  case  of  pelvic
umours,  the  urinary  tract  can  be  viewed  (Fig.  4)  on  arpretation using CT (a). Axial T2 MRI perfectly showing adipose
arrow) following pelviglossectomy, bilateral functional lymph node
 known, moderately differentiated, epidermoid carcinoma of the
ion  from  it.  The  beneﬁt  is  greater  than  the  constraints
onnected  with  the  injection  [4],  which  include  the  need
o  train  radiotherapy  operators  (in  infusions),  to  acquire  a
344  J.  Thariat  et  al.
Figure 2. CT/MRI fusion in ENT identiﬁcation imaging. When MRI can be performed (taking account of any contraindications) and inter-
preted (absence of movement artefacts), it is superior to a CT scan, even with injection. (a): CT without injection not contributing anything
useful. Metal hardening artefacts of the X-ray beam (dental amalgam) that do not interfere in contrast-enhanced MRI (b). MRI detects a
subangulomandibular adenopathy (oblique arrow), enhancement of the masseter (horizontal arrow) and of the retrostyloid space (verti-
cal arrow) to be taken into account in radiotherapy management of this cystic adenoid carcinoma of an accessory salivary gland of the
oropharynx.
Figure 3. CT/MRI fusion. Axial plane of a recurring epidermoid cancer of the right palatine tonsil extending to the base of the tongue,
the soft palate and to the infratemporal fossa. Contralateral location. (a): Contrast-enhanced CT shows extension of the lesion better than
CT and T1-weighted MRI without injection (b), but is less precise than MRI with injection as regards the extension to the infratemporal
fossa, the soft palate and the bone marrow (c) (mandible-arrow). (d): T2-weighted axial slice with fat saturation (CSF white), blur due to
movement by the patient (a major disadvantage of MRI).
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Figure 4. Axial CT slices of the pelvis, in the delayed phase. Invasive bladder carcinoma with diffuse parietal thickening; scan performed
ancerous bladder wall and the terminal ureters (arrows) are outlined.
.
Figure 5. Frontal MRI section passing through the foramina ovales
and the infratemporal fossae for a cystic adenoid carcinoma of an
accessory salivary gland of the left oropharynx. Besides better con-
trast resolution of the soft tissues, by visualising the cranial nerves
the extension of the neurotropic tumour of this cystic adenoid car-
cinoma to the base of the skull then to the Gasser lymph node (Vth
cranial pair) can be clearly identiﬁed, without visible enlargement
of the left foramen ovale in CT (arrows). Contouring will there-
fore have to take this endocranial extension, which is still clinically
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obefore identiﬁcation and contouring. In the excretory phase the c
Identiﬁcation should take account of the degree of bladder fullness
nonionic  iso-osmolar  contrast  medium  in  particular,  and  an
injector  for  undertaking  a  bolus.  The  risk  in  injecting  iodine
is  twofold.  The  risk  of  anaphylactic  shock  means  the  pres-
ence  of  medical  staff  is  necessary  during  injection,  in  the
room  containing  the  scanner  for  radiotherapy,  with  premed-
ication  possibly,  if  allergy  is  suspected  [4,5]. The  second,
lesser  known  risk  is  of  nephropathy  induced  by  the  contrast
agent  (contrast-induced  nephropathy  — CIN),  which  is  all
the  higher  if  the  patient  is  diabetic,  elderly,  dehydrated,
and  if  the  product  injected  is  ionic  and  hyperosmolar  [6].
This  means  systematic  control  of  creatinine  clearance  in  any
patient  at  risk,  i.e.  meeting  one  of  the  items  on  the  Choyke
questionnaire  positively  [7].
The  use  of  multimodality  imaging  [8]  may  sometimes  be
substituted  for  iodine  injection  at  the  time  of  the  dosimetry
scan,  but  other  than  for  strictly  intracranial  tumours,  the  use
of  imaging  for  diagnostic  purposes,  which  is  not  in  a  position
to  treat  and  therefore  has  no  radiotherapy  restraint,  implies
inexact  registration  of  the  various  imaging  modalities.  Cal-
culation  of  the  dose  is  modiﬁed  by  2—3%  with  2D-3D,  as
iodine  creates  a  hyperdense  sector,  which  absorbs  the  dose
at  a  place  where  there  will  no  longer  be  any  iodine  during  the
treatment  sessions.  While  the  impact  of  the  contrast  agent
on  dose  calculation  seems  lower  than  the  beneﬁt  expected
from  contouring,  the  dose  delta  may  be  more  signiﬁcant
with  the  use  of  mini-beams  (stereotactic  radiotherapy)  and
steep  gradient  techniques.  A  simple  means  of  correcting
this  is  to  perform  two  scans  during  simulation,  one  with-
out  injection  for  dosimetry  and  contouring  of  the  organs
at  risk  (OAR),  and  the  other  with  injection,  for  contour-
ing  the  target  volumes.  Irradiation  related  to  the  additional
scan  is  low  at  about  5  to  20  mSv.  The  use  of  multimodality
imaging  can  signiﬁcantly  improve  understanding  and  con-
touring  of  target  volumes,  particularly  of  tumour  extensions
(Fig.  5).  MRI,  therefore,  and  particularly  functional  MRI  (per-
fusion,  permeability),  has  become  essential  for  contouring
oligodendrogliomas  which  can  have  margins  of  2—3  cm  by
contouring  done  on  a  scan  alone,  and  even  with  MRI  if
standard  sequences  are  used  [9].  With  better  spontaneous
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osymptomatic, into account.
esolution  than  the  scan,  MRI  very  often  requires  the  injec-
ion  of  gadolinium  chelates  to  enhance  contrast  of  vascular
esions  and  blood  vessels.  In  neuropathology,  the  injection
f  gadolinium  salts  shows  rupture  of  the  blood/brain  barrier
erfectly,  as  well  as  the  foci  of  possible  dissemination  to  the
ontralateral  hemisphere  or  to  the  subependymal  region.
owever,  one  disadvantage  recently  discovered  is  the  risk
f  nephrogenic  systemic  ﬁbrosis  (NSF)  below  a  creatinine
3c
h
o
a
k
c
o
t
w
s
t
w
p
i
t
i
p
p
i
t
a
w
p
o
p
i
w
a
E
t
r
T
o
o
t
a
a
g
t
o
t
c
o
p
i
p
h
u
a
t
p
c
u
d
a
s
t
d
p
a
c
[
h
o
e
c
r
b
a
F
j46  
learance  threshold  of  25  ml/min  [10]. The  risk  of  NSF  varies
owever  depending  on  the  type  of  contrast  product  used.
For  organs  at  risk,  these  uncertainties  and  the  variability
f  contouring  depend  on  the  operator’s  (the  radiother-
pist’s  and  sometimes  the  dosimetrist’s)  radioanatomical
nowledge,  and  on  whether  recommendations  have  been
irculated  which  ﬁx  common  rules.  Contouring  certain
rgans  at  particular  risk  requires  speciﬁc  imaging  modali-
ies.  Contouring  the  cochlea,  for  example,  requires  a  bone
indow  and  scanning  in  one  millimetre,  or  even  thinner,
lices.  A  radiotherapy-planning  scan  is  best  for  contouring
he  cochlea  in  two  or  three  slices,  and  is  usually  performed
ith  slices  of  2.5  mm.  To  compare  treatment  plans  and
rospective  documentation  of  doses  to  organs  at  risk,  it
s  essential  to  have  a  common  deﬁnition.  When  (percep-
ion/sensorineural)  hearing  is  to  be  evaluated,  should  the
nner  ear  be  contoured  and  what  does  that  include?  In
ractice,  it  means  contouring  the  cochlea  alone,  but  some
ractitioners  also  include  the  semi-circular  canals  (involved
n  balance).  Structures  previously  considered  as  non-speciﬁc
issues,  because  they  are  impossible  to  contour  routinely
nd  cannot  be  spared,  given  the  irradiation  technique  used,
ill  be  increasingly  taken  into  account  in  future  treatment
lans.  It  will  thus  be  possible  to  make  the  signs  of  sec-
ndary  effects  of  irradiation  clear,  and  document  series  or
arallel  dose/volume/effect/organ  correlations.  Consider-
ng  the  time  already  allotted  to  contouring,  computer  tools
ill  probably  make  contouring  these  ‘‘new’’  organs  at  risk
utomatic.
valuation of intervariability in contouring
arget  volumes, contouring tools and
esources usedo  contour  treatment  volumes  (GTV  and  the  probability
f  microscopic  extension  [CTV],  as  well  as  determination  of
rgans  at  risk  [OAR]),  medical  expertise  is  required  to  deﬁne
o
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igure 6. Interobserver variability of contouring (four observers: yel
ugular lymph nodes (b).J.  Thariat  et  al.
he  GTV  that  is  based  on  good  knowledge  of  radioanatomy
nd  radiodiagnostic  protocols  (the  injection  of  contrast
gent  for  a  planning  scan  and  consultation  with  radiolo-
ists  for  MRI),  and  on  good  knowledge  of  the  history  of  the
umoral  disease  in  terms  of  dissemination,  for  each  type
f  tumour,  to  deﬁne  the  CTV.  Intra-  and  interobserver  con-
ouring  variations  may  be  greater  than  the  uncertainties
onnected  with  positioning  the  patient  or  with  movement
f  the  organs  [11,12].  There  are  variations  in  contouring  the
arotid  glands  and  ENT  lymph  nodes  (Fig.  1),  despite  val-
dated  recommendations  (Fig.  6).  In  order  to  standardise
ractices,  learned  societies,  cooperation  groups  and  teams
ave  suggested  tools  to  help  deﬁne  and  contour  target  vol-
mes  and  organs  at  risk.  The  use  of  standard  protocols  and
n  atlas  to  help  contouring,  or  an  automatic  segmenta-
ion  atlas,  helps  reduce  intervariability.  Indeed,  in  pelvic
athology,  the  deﬁnition  of  presacral  and  iliac  lymph  nodes
an  vary  by  a  factor  of  10  [13]. For  prostate  cancers,  vol-
mes  can  vary  by  a  factor  of  5  (4  to  19  cm3) with  a  median
eviation  of  9  cm3 [14]. Contouring  the  mammary  gland  on
 scan  suffers  from  intra-observer  but  especially  interob-
erver  variation  [15]. This  can  have  repercussions  on  the
herapy,  which  may  be  considerable  if  there  is  partial  irra-
iation  of  the  breast,  with  differences  observed  in  the  three
lanes  and  particularly  between  right  and  left  [16]. There
re  other  comparisons  in  pulmonary  cancers  [17]  and  can-
er  of  the  uterine  cervix  (particularly  for  brachytherapy)
18,19].  The  impact  of  apprenticeship  was  evaluated  among
ouse  ofﬁcers  in  training  and  emphasizes  the  importance
f  practical  and  theoretical  training  courses.  Eleven  delin-
ations  of  a  T2N2b  tumour  of  the  base  of  the  tongue  were
ollected  before  and  after  a  theory  course  at  the  Memo-
ial  Sloan-Kettering  Cancer  Center  [20]. The  training  given
y  experts  reduced  the  interobserver  variability.  A  similar
pproach  was  undertaken  in  France  and  concerned  a  case
f  epidermoid  carcinoma  of  the  right  upper  lobe,  staged
2N2M0  [21]. The  expansions  were  modiﬁed  after  training
21].  Bearing  in  mind  contouring  variability,  one  guaran-
ee  of  quality  during  attempts  at  therapy  is  to  simulate
low, red, light blue, dark blue) of the parotid (a), and the upper
ion  p
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treatment  in  a  dummy  run:  each  participating  centre  con-
ducts  dosimetry  on  a  virtual  patient  with  a  reference
common  to  the  trial  centres.  Quality  assurance  studies  are
conducted  [22,23]  allowing  the  conformity  of  practices  to
be  veriﬁed  or  to  be  modiﬁed,  if  necessary.  Another  way  of
standardising  contouring  is  by  using  paper  or  online  con-
touring  atlases.  A  site  for  self-training  in  contouring  was
set  up  in  October  2008  (www.siriade.org).  AFCOR  (Associa-
tion  de  Formation  Continue  en  Oncologie  Radiothérapie  [the
French  association  for  continuous  training  in  radiotherapy
oncology])  (http://www.afcorfmc.org/) offers  continuous
training  seminars  and  theoretical  and  practical  courses  to
house  ofﬁcers  and  practitioners,  to  teach  delineation  tech-
niques  and  check  the  quality  of  volumes  contoured.  Training
programs  have  been  designed  for  this  step  in  standardising
contouring,  which  moreover  permit  comparison  of  treat-
ment  plans  for  contours  delineated  and  for  the  dosimetry
results  obtained  using  indexes.  The  quality  of  the  treatment
plan  is  evaluated  by  a  visual  dosimetric  analysis,  slice  by
slice,  or  by  viewing  the  spatial  organisation  of  the  tumour,
critical  organs  and  isodoses  in  the  form  of  quantitative
three-dimensional  dose  distribution,  represented  by  dose-
volume  histograms  (DVH).  These  DVH  give  the  values  of  the
maximal,  minimal,  mean  and  modal  doses  delivered  in  each
volume  of  interest,  as  well  as  the  dose  delivered  per  unit  or
per  volume  percentage  of  these  structures.  As  a  result  of
technological  developments  in  radiotherapy  planning  sys-
tems,  various  treatment  plans  for  a  single  patient  can  be
relatively  rapidly  obtained.  The  choice  between  several
options  ensuring  the  same  tumour  coverage  and  the  same
protection  of  critical  organs  generally  favours  the  option
that  best  spares  healthy  tissues,  with  the  simplest  ballistics
or  the  less  expensive  treatment.  Any  detailed  comparison
between  several  treatment  plans  is  still  difﬁcult  however,
and  not  readily  reproducible.  Integration  and  analysis  of
all  this  information  would  require  a  tool  that  could  collate
all  the  dosimetric  data  into  a  score  or  index,  which  would
express  the  relationship  between  the  irradiated  tumour  tis-
sue  and  non-irradiated  healthy  tissues,  and  would  harmonise
dosimetry  validation.  The  conformity  index,  a  geometrical
index  representing  the  ratio  between  the  reference  isodose
volume  and  the  target  volume,  was  created  in  1993  by  the
Radiation  Therapy  Oncology  Group  (RTOG)  and  meets  this
objective  but  does  not  allow  all  the  requirements  of  an
ideal  dosimetry  plan  (100%  of  the  dose  to  the  tumour,  0%
to  healthy  organs)  to  be  veriﬁed,  because  it  does  not  take
account  of  healthy  organs.  It  is  the  same  for  the  cover-
age  index  and  the  homogeneity  index.  To  these  geometrical
indexes  are  added  dosimetry  indexes  (for  example,  the  inte-
gral  dose  or  energy  delivered  to  the  patient  in  joules,  the
dose  gradient  or  mean  of  the  decrease  in  dose  in  %  per  mm
between  the  isodose  prescribed  and  50%  of  the  isodose),
or  radiobiological  indexes  such  as  the  biological  equivalent
dose  (BED,  or  equivalent  uniform  dose,  EUD)  which,  when
distributed  uniformly  in  the  target  volume,  induces  the  same
number  of  clonogenic  cells  as  the  dose  in  Gy  prescribed.
These  indexes  are  still  not  in  general  use  on  a  routine  basis,
probably  again  through  lack  of  experience,  and  because
most  TPS  do  not  provide  them  in  a  simple  manner.
Radioanatomy  tools  are  moreover  accessible  on  line
(e-anatomy)  as  are  also  proposals  for  contouring,  based
on  atlases  for  certain  target  volumes  and  organs  at  risk:
t
t
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he  lymph  nodes  in  ENT,  gynaecological  cancers,  anorectal
ancers,  the  pelvic  lymph  nodes  in  prostate  cancers,  the
rachial  plexus,  breast  cancers  (such  as  those  suggested
y  the  RTOG  http://www.rtog.org/atlases/contour.html).
ome  constructors  offer  automatic  segmentation  atlases,  in
articular  for  organs  at  risk  or  for  the  cervical  lymph  nodes;
ost  are  still  being  clinically  evaluated  [24].
Similarly,  great  variability  has  been  shown  in  decisions
oncerning  dosimetry  [25]. Variability  in  contouring  tar-
et  volumes  and  also  in  making  dosimetry  choices,  with
onsiderable  discrepancies  of  several  percentage  points  on
ose-volume  histograms,  was  noted  for  a  case  of  paedi-
tric  nephroblastoma,  using  a program  for  intercomparison.
his  experience  highlights  a  certain  lack  of  knowledge  of
osimetry  correlations  with  the  occurrence  of  late  toxic-
ty  and  the  need  for  prospective  data  from  national  and/or
nternational  databases  [25].
mage networks
ith  the  development  of  image  networks,  such  as  the
ne  initially  set  up  for  the  European  Organization  for
esearch  and  Treatment  of  Cancer  protocol,  Groupe  d’étude
es  lymphomas  de  l’adulte  (EORTC—GELA-IIL  H10),  it  has
een  possible  to  exchange  data  securely  throughout  France
ince  2007  (including  images,  contouring,  irradiation  ﬁelds,
osimetry,  as  well  as  histopathological  examination  slides,
atients’  ﬁles,  etc.)  in  the  DICOM  and  DICOM-RT  format
Fig.  7)  [26]. With  such  networks,  ﬁles  can  be  exchanged
etween  anti-cancer  centres,  as  well  as  university  and
egional  hospital  centres.  They  permit  prospective  and
etrospective  quality  controls.  Wider  implementation  of
hese  networks  is  currently  being  slowed  by  the  human
actor,  despite  a  simple  procedure  and  their  deﬁnite
dvantage.
nnovative irradiation techniques/Pooled
echnical platforms
n  view  of  the  sophistication  of  radiotherapy  technical
latforms,  several  departments  may  share  one  piece  of
quipment,  particularly  when  implementing  innovative  irra-
iation  techniques.  To  plan  the  ﬁrst  stages  of  treatment
contouring,  dosimetry),  limit  the  mobilisation  of  staff
radiotherapists,  physicists,  dosimetrists  etc.)  and  organ-
sational  constraints,  and  overcome  the  disadvantages  of
his  geographical  separation,  departments  are  equipped
ith  consoles,  assigned  to  the  planning  stages,  on  each
f  the  user  sites.  These  consoles  are  linked  to  clusters
hat  store  the  planning  data.  Treatment  machines  then
uery  these  servers,  to  start  the  treatment.  Because  of
he  network  architecture,  planning  sites  can  be  separate
rom  treatment  sites.  The  doctors  referring  patients  never-
heless  generally  have  a  consultation  with  their  patients,
o  monitor  them  during  the  course  of  treatment,  on  the
reatment  site.  This  organisation  presupposes  good  coordi-
ation  between  teams,  with  a  continuous  physical  medical
resence.
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ixed techniques/Adaptive radiotherapy
s  innovative  techniques  are  sometimes  complementary,
uch  as  intensity-modulated  conformal  radiotherapy  (IMCRT)
nd  stereotactic  radiotherapy,  this  results  in  treatment
lans  being  disseminated  that  combine  a  mix  of  tech-
iques  [27,28].  Using  treatment  planning  systems  that  differ
etween  these  techniques  requires  the  use  of  dose  summa-
ion  software.  Similarly,  the  use  of  adaptive  radiotherapy
ART),  consisting  of  re-planning  treatment  when  morpho-
ogical  modiﬁcations  have  been  observed  during  irradiation,
eeds  the  ability  to  recalculate  cumulative  doses  on  a  rou-
ine  basis,  simply  and  rapidly.  This  concept  of  adaptation
o
m
b
igure 8. Adaptive radiotherapy based on a replanning CT scan during
ays before the 1st session of irradiation (dose received zero = 0 Gy); p
: signiﬁcant tumoral reduction observed of the adenopathies of a mo
ustifying recontouring and calculation of the cumulative dose as a funcpeutic trial.
s  not  new,  since  cervical  thickness  or  the  size  of  cervical
denopathies  has  been  measured  for  decades  during  irra-
iation  of  the  ENT  region  to  adapt  the  energy  if  there  is
 reduction  (Fig.  8),  following  Bataini’s  example,  in  order
o  modify  ﬁelds  depending  on  their  clearance.  Neverthe-
ess,  starting  in  about  2005,  adaptive  radiotherapy  is  now
sing  imaging  and  in  particular,  image-guided  radiotherapy
IGRT).  Dosimetry  tools  make  it  possible  to  accurately  calcu-
ate  cumulative  doses  depending  on  adaptations  secondary
o  morphological  changes  (tumour  reduction  (Fig.  3)  or  loss
f  weight  by  the  patient)  observed  in  the  course  of  treat-
ent  [29]. The  clinical  and  medical  beneﬁt  of  ART  has  not
een  validated,  but  many  prospective  studies  are  underway
 the 4th week of irradiation. a: planning CT scan performed eight
erformed at the 16th session of irradiation (dose received 30 Gy);
derately differentiated epidermoid carcinoma of the oropharynx,
tion of these changes.
ion  p
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[Radiotherapy  and  radiology:  Joint  efforts  for  modern  radiat
[30]. A  reduction  in  the  bilateral  volume  of  the  parotid
glands  of  17%  and  of  the  target  volume  of  5%  has,  for  exam-
ple,  been  shown  on  the  17th  day  of  irradiation  by  IMCRT
of  oropharyngeal  carcinomas  in  situ,  making  it  necessary  to
recontour  the  volumes  and  recalculate  the  doses  accumu-
lating  from  the  treatment  already  given  and  from  that  to
come  [30].
Conclusion
Improvement  in  the  quality  of  irradiation,  owing,  partic-
ularly,  to  the  ballistic  possibilities  of  new  techniques,  is
associated  with  a  requirement  for  standardisation,  pre-
cision,  reproducibility  and  safety.  Training  and  advisory
programmes  have  been  set  up  over  recent  years  due  to
this  need  for  standardisation  and  for  quality  in  radiotherapy
practice.  Implementing  innovative  radiotherapy  techniques
also  relies  on  tools  such  as  multimodality  imaging  (major  role
of  radiologists  during  radiation  therapy  planning),  image
networks,  dose  summation  programs,  etc.,  which  have
indeed  become  indispensable  for  precision  radiotherapy  of
quality.
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